MTOR and Guillain-Barre syndrome: Also, mutations in the tumor suppressor gene PTEN, the protein that inactivates the PI3K/AKT/mTOR pathway, are frequent events in GBs and are associated with therapeutic resistance (Benitez et al., 2017).